Orphazyme's creditors left without real options
![Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13883003.ece/ALTERNATES/schema-16_9/20210618-130534-5-4032x2263ma.jpg)
Uncertainty continues to surround Orphazyme’s future, even after the proposal of a restructuring plan by the Danish biotech company’s leadership and the restructuring administrator, Gorrissen Federspiel’s John Sommer Schmidt.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme confirms delisting in the US
For subscribers